The 5000% case: a glimpse into the financial issue of lung cancer treatment [1]
This is an outstanding and provocative editorial comment concerning treatment costs of lung cancer based on an article published in the last issue of the European Respiratory Journal. It reveals discrepancies in access to new therapies based on therapeutic targets due to molecular testing and treatment costs.